Navigation Links
VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists
Date:2/13/2008

Could have impact on cancer treatment and other systemic uses of drugs to

target vascular endothelial growth factor (VEGF)

BOSTON, Feb. 13 /PRNewswire/ -- New research by scientists at Schepens Eye Research Institute may help explain why the anti-cancer drug Avastin, which targets a growth factor responsible for creation of new blood vessels, causes potentially fatal brain inflammation in certain patients. Institute scientists mimicked the drug's activity in mice and found that it damaged the cell lining that prevents fluid from leaking from the ventricle into the brain. The ventricle is the structure in the brain that holds cerebral spinal fluid after it is produced and which is continuous with the spinal cord. The results are currently published online (on February 11th) in The Journal of Experimental Medicine.

"This finding is significant because it may ultimately modify the way we use systemic drugs that block blood vessel growth, and it also suggests that VEGF (vascular endothelial growth factor) plays a more extensive role in the body than we previously thought," says Dr. Patricia D'Amore, senior scientist at Schepens Eye Research Institute and principal investigator of the study.

The cancer drug Avastin (bevacizumab) is used to treat advanced bowel cancer in combination with chemotherapy. By targeting VEGF, Avastin inhibits the growth of tumors by cutting off their blood supply and thus depriving them of oxygen and other nutrients. In a small percentage of patients, however, Avastin can cause neurological side effects, ranging from headaches and blurry vision to potentially fatal seizures and brain swelling.

D'Amore and her team found that VEGF normally protects the specialized cells that create a seal between the brain and ventricle and thus prevent fluid from leaking into the brain. When VEGF was blocked in mice, these cells were damaged and the animals developed brain lesions. The authors suspect that Avastin's side effects in humans may be caused by a similar phenomenon. Why these symptoms occur in only a few patients is not yet known.

Authors of the study include: Arindel S.R. Maharaj(2,3), Tony E. Walshe(2,3), Magali Saint-Geniez(2,3), Shivalingappa Venkatesha(2,4), Angel E. Maldonado (2,3), Nathan C. Himes(2), Kabir S. Matharu(3), S. Ananth Karumanchi(2,4) and Patricia A. D'Amore(1,2,3)

(1) Departments of Ophthalmology and Pathology

(2) Harvard Medical School

(3) Schepens Eye Research Institute

(4) Center for Vascular Biology, Departments of Medicine, Obstetrics,

Gynecology, Surgery and Pathology, Beth Israel

Deaconess Medical Center.

Schepens Eye Research Institute is an affiliate of Harvard Medical School and the largest independent eye research institute in the nation.


'/>"/>
SOURCE Schepens Eye Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VEGF neutralization can damage brain vessels, say Schepens Eye Research Institute scientists
2. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
3. Anti-cancer drug damages brain vessels
4. Novel compound may lessen heart attack damage
5. Gene predicts heart attack response and cardiac damage
6. Regular marijuana use increases risk of hepatitis C-related liver damage
7. Over-the-counter eardrops may cause hearing loss or damage
8. Over-the-counter eardrops may cause hearing loss or damage
9. Evolution of human genomes guardian gives people unique protections from DNA damage
10. Priming Heart Before an Attack Could Limit Damage
11. Genes identified that protect against heart damage from chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: